Ibogaine: Information and Guidelines for Integrated Therapy
AI-extracted · unverified · confirm at source
Comprehensive NZ operational manual: inclusion criteria, pre-acceptance screening, medication contraindications, emergency response protocols, consent forms, risk management for regulated therapy.
Dosing: 10–22 mg/kg (treatment range); 200mg test dose; minimum 72h monitoring (oral)
Safety data present: QTC, ELECTROLYTE
Contraindications: Prolonged QT interval, Cardiac issues (pericarditis, history of cardiac problems, elevated cholesterol), Compromised liver function (active chronic HepC >4x normal range), Kidney or gastro-intestinal disease, Active neurological/psychiatric disorders (psychosis, bipolar, schizophrenia, organic brain disease, dementia requiring ongoing treatment), Cerebellar dysfunction, epilepsy, Pregnancy/breastfeeding (unless weaning plan incorporated prior to treatment), CYP2D6-metabolised drugs (inhibitors in particular; caution with inducers and substrates), Anticonvulsants, anti-epileptics, antidepressants, neuroleptics, antipsychotics, Serotonergic drugs, Centrally acting drugs, QT-prolonging drugs (caution), Substances inducing hypokalaemia or hypomagnesaemia, Steroids, hormones, depo-injection drugs (caution; corticosteroids may induce psychological disturbances), Naloxone (inhibitor of ibogaine metabolic pathway), Synthetic cannabinoids (minimum 10-day abstinence required), Alcohol (minimum 7-day abstinence prior to treatment), Methadone >50mg (must reduce to <50mg; switch to short-acting opioid preferred), Suboxone/subutex (must switch to short-acting opioid minimum 6 weeks prior)